- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Livingston Securities (www.livingstonsecurities.com) held their first of a series of webinars covering innovation and dealmaking trends in healthcare and life sciences on June 25, 2009. Participants in the Livingston Securities "627 Club" webinars gain important insights into investment and business opportunities in nanotechnology-focused companies across multiple sectors. Healthcare and Life Sciences have been of particular interest to investors in recent months, and these webinars will continue over the summer leading up to the 2nd annual Livingston Securities Healthcare Advanced and Nanotechnology Investor Summit on September 24, 2009 in New York City.
The Livingston Securities Healthcare Webinar featured panelists from venture capital, private equity, pharmaceutical executives, advisors to the Obama administration, startups and emerging public companies, all discussing the current status of healthcare and life science investments, along with emerging models for M&A and partnerships.
The webinar was chaired by Dr. Mostafa Analoui, Head of Healthcare & Life Sciences for the Livingston Group of Companies . Panelists included Dr. David Collier, Managing Director of CMEA Capital, Dr. Michael Nowak, Managing Director at Yorkville Advisors, Dr. Gil Omenn, Director of the Center for Computational Medicine & Biology at University of Michigan and former President of the American Association for the Advancement of Science, Dr. Michael Krams, Vice President of Wyeth, Dr. Eugene Seymour, CEO of NanoViricides and Mr. Rodney Brown, CEO of PharmaNova.
Key topics included the current state of VC funding for healthcare and life science companies, impact of the recent credit crunch and lack of IPOs on VC-backed companies, as well as future directions for creative financing and deal making. Private equity strategies for mergers and acquisitions were presented by a number of PE firms in healthcare. Other discussions included plans to achieve universal health care and the impact on cost and pricing, and the impact on venture investment in research & development, and innovative methods for design and execution of clinical trials. CEOs representing early stage public and private companies described their business strategies for financial viability and innovative models for collaborations and product development.
Livingston Securities will hold its 2nd webinar covering healthcare investment trends on Monday, July 27, 2009. For details please contact or visit our website at www.livingstonsecurities.com.
About Livingston Securities
Livingston Securities is dedicated to providing corporate finance and strategic advisory services to corporate clients and sales, trading and related services to institutional investors and high net worth individuals who focus on disruptive technologies and their impact on healthcare, energy, infrastructure and other leading sectors of the American and global economy. Our goal is to provide a unique perspective and expertise on investments in nanotechnology and in companies that are commercializing and/or impacted by scientific advances in the emerging field of nanotechnology.
For more information, please click here
For Livingston Securities
Steven Wright-Mark, 212-677-8700 ext. 29
Copyright © Business Wire 2009If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Artificial synapse rivals biological ones in energy consumption June 21st, 2016
Nanometrics Announces Upcoming Investor Events May 10th, 2016
Stealth nanocapsules kill Chagas parasites in mouse models June 22nd, 2016
FEI Launches Helios G4 DualBeam Series for Materials Science: The Helios G4 DualBeam Series features new capabilities to enable scientists and engineers to answer the most demanding and challenging scientific questions June 27th, 2016
Call for NanoArt and Art-Science-Technology Papers June 9th, 2016
Novel gene therapy shows potential for lung repair in asthma May 18th, 2016